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Purpose: Surgical resection for gastric adenocarcinoma is associated with significant 
post-operative morbidity and mortality. The aim of this study was to assess the prognostic 
significance of sarcopenia in patients undergoing resection for gastric adenocarcinoma with 
respect to post-operative morbidity and survival.
Materials and Methods: A retrospective analysis was conducted on a cohort of consecutive 
patients who underwent surgical resection for gastric adenocarcinoma between 2008 and 
2014. Patient demographics, radiological parameters, and pathological data were collected. 
OsiriX software (Pixmeo) was used to measure skeletal muscle area, which was normalized 
for height to calculate skeletal muscle index.
Results: A total of 56 patients (41 male, 15 female; mean age, 68.4 ± 11.9 years) met the 
inclusion criteria. Of these, 36% (20 of 56) of the patients were sarcopenic pre-operatively. Both 
sarcopenic and non-sarcopenic patient groups were equally matched with the exception of 
weight and body mass index (P=0.036 and 0.001, respectively). Sarcopenia was associated with a 
decreased overall survival (log-rank P=0.003) and was an adverse prognostic predictor of overall 
survival in multivariate analysis (hazard ratio, 10.915; P=0.001). Sarcopenia was a predictor of 
serious in-hospital complications in multivariate analysis (odds ratio, 3.508; P=0.042).
Conclusions: In patients undergoing curative resection for gastric cancer, there was a 
statistically significant association between sarcopenia and both decreased overall survival 
and serious post-operative complications. The measurement and reporting of skeletal muscle 
index on pre-operative computed tomography should be considered.
Keywords: Sarcopenia; Stomach neoplasms; Prognosis; Morbidity; Tomography, 
X-ray computed
INTRODUCTION
Gastric cancer is the fifth most common malignancy worldwide and comprises 6.8% of all cancers 
diagnosed. It is the third leading cause of cancer-related deaths worldwide [1]. There is a wide 
geographical variation in the incidence of cases, with countries in Eastern Asia, such as South Korea 
and Japan, having age-standardized incidence rates of 41.8 and 29.9 per 100,000, respectively [1], 
while in the United States, an approximate incidence of 7.3 per 100,000 is observed [2].
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Sarcopenia and Post-Operative 
Morbidity and Mortality in Patients 
with Gastric Cancer
Gastric cancer has a poor 5-year overall survival (OS) rate of 30.6% [2], with surgical 
resection being the only curative intervention [3]. Post-operative complications have been 
reported to be as high as 39% in patients undergoing surgery with curative intent [4]. 
A recent study on patients undergoing potentially curative total gastrectomy for gastric 
adenocarcinoma indicated that 28% of patients required invasive post-operative intervention, 
based on the grading of the interventions performed (Clavien-Dindo classification) [5].
A number of recent studies have demonstrated an adverse association between sarcopenia 
and immediate and long-term patient outcomes following surgery, including post-operative 
complications, length of hospital stay, recurrence-free survival (RFS), and OS [6-8]. 
Sarcopenia is defined by the European Working Group on Sarcopenia in Older People as a 
low muscle mass and either decreased muscle strength or low physical performance [9]. The 
deleterious effect of sarcopenia on patient outcomes has been shown to be significant in a 
number of different cancers such as colorectal and liver cancers.
The skeletal muscle index is used to diagnose sarcopenia and this index may be calculated 
using computed tomography (CT). CT constitutes an important aspect of patient assessment 
prior to surgical triage and all such patients will undergo pre-operative staging CT. The 
calculation of skeletal muscle index on CT prior to surgery may provide addition useful 
information pertaining to the patient's condition and could help guide patient preparation 
and counselling. The aim of this study was to investigate the association between sarcopenia 
in patients undergoing surgery for gastric cancer and their post-operative outcomes in terms 
of morbidity, RFS, and OS.
MATERIALS AND METHODS
The local Institutional Review Board granted ethical approval (approval number ECM 4 
(cc) 04/04/16). All consecutive patients who underwent surgery with curative intent for 
gastric adenocarcinoma between January 1, 2008 and December 31, 2014 in a single tertiary 
referral center by one surgeon were included in this study. Patients were identified through 
surgical logbooks and cross-verified using the histopathology database confirming the 
diagnosis of gastric adenocarcinoma according to the American Joint Committee on Cancer 
(AJCC) staging system [10]. Pathological data including tumor location and stage were 
collected from this database. Patient medical records were analyzed to obtain pre-operative 
clinical demographics, including age, sex, date of surgery, use of neoadjuvant therapy, and 
the identification of patients' comorbidities. The Charlson comorbidity index (CCI) was 
calculated from patient pre-operative information [11].
Peri-operative reports were used to obtain patients' height, weight, and the American 
Society of Anesthesiologists physical status (ASA-PS) [12]. Post-operative information was 
obtained from patient medical records to include the occurrence of complications, which 
were graded according to the Clavien-Dindo classification system [13]. The total number of 
intensive care unit (ICU) and hospital bed days were obtained from the hospital inpatient 
medical system. Follow-up information regarding tumor recurrence and mortality were 
obtained from medical and radiological records. OS was defined as the length of time from 
the date of first therapy to the date of death or loss to follow-up. RFS was defined as the 
length of time from the date of first therapy to the date of detection of tumor recurrence, 
death, or loss to follow-up.
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Diagnostic work-up and imaging
All patients were discussed at a multi-disciplinary team meeting. As part of the routine pre-
operative diagnostic procedure, all patients underwent an esophagogastroduodenoscopy 
and a staging CT scan of the thorax, abdomen, and pelvis [14]. In all, 80.4% (45 of 56) of the 
patients had an endoscopic ultrasound for loco-regional staging and 73.2% (41 of 56) of the 
patients had a staging laparoscopy with peritoneal washings. Survival analysis was performed 
on data from the pre-operative CT or from before commencement of chemotherapy where 
applicable. Morbidity analysis was performed on data from the staging CT performed before 
surgery irrespective of whether chemotherapy was administered as this reflected the patient's 
skeletal muscle index entering surgery, which could be affected by the administration of 
chemotherapy. CT scans were electronically stored on the hospital imaging system. Pre-
operative CT scans for the identified study patients were anonymized by a third-party 
imaging technician.
Image analysis
CT scans were analyzed using the OsiriX version 5.6.1 open source software (32-bit, Pixmeo, 
Geneva, Switzerland; http://www.osirix-viewer.com). The cross-sectional skeletal muscle 
area (cm2) was measured using a standardized approach [8,15]. Two sequential scans at the 
level of the third lumbar vertebra, in which both transverse processes were visible, were used. 
The grow/regrow tool was used to measure the skeletal muscle area on these axial slices by a 
reviewer blinded to the patients' demographics. The threshold range for skeletal muscle was 
−30 to +150 Hounsfield units [16,17]. The skeletal muscles included were the psoas, paraspinal, 
and abdominal wall muscles. The average muscle area of these 2 slices was used. The skeletal 
muscle area was normalized for height to calculate the skeletal muscle index [18]. The specific 
cut-off values used for sarcopenia were 52.4 cm2/m2 for men and 38.5 cm2/m2 for women, as 
published by Prado et al. [17]. An example of an analyzed CT scan is shown in Fig. 1.
Statistical analysis
Statistical analysis was performed using the Statistical Package for the Social Sciences (SPSS) 
v20.0 software (SPSS Inc., Chicago, IL, USA). The independent t-test and Mann-Whitney 
U test were used to compare continuous variables including age, number of positive lymph 
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Fig. 1. Axial CT scan of a 77-year-old sarcopenic male with a skeletal muscle index of 41.58 cm2/m2. The total 
skeletal muscle area (indicated in purple) was measured on a CT slice at the level of L3. 
CT = computed tomography.
nodes (LNs), number of LNs resected, patient height, weight, and body mass index (BMI). 
The χ2 test and Fisher's exact test were used to compare categorical variables such as sex, 
tumor site, TNM stage, use of neoadjuvant therapy, ASA-PS grade, and CCI score. The impact 
of sarcopenia on morbidity was analyzed by univariate and multivariate regression analyses. 
Morbidity was assessed according to serious in-hospital complications (Clavien-Dindo ≥3a), 
the number of ICU bed days, and the total length of hospital stay. OS and RFS were evaluated 
by Kaplan-Meier survival analysis and the log-rank test. The association of sarcopenia with 
OS was analyzed using univariate and multivariate Cox regression analyses. Graphs were 
constructed on GraphPad Prism v6.07 (GraphPad Software Inc., La Jolla, CA, USA). A P-value 
of <0.05 was used as the level of significance for the study.
RESULTS
A total of 56 patients (41 male, 15 female; mean age, 68.4 ± 11.9 years) were included in 
the study. Follow-up was completed for all included patients. There was a mean of 28 days 
(range, 0–74 days) from the date of CT scan to the date of surgery. The majority of the 
patients (87.5%, 49 of 56) had the CT scan within 6 weeks of the surgery. In all, 20 patients 
(35.7%) were sarcopenic pre-operatively, which included three of 29 patients who received 
neoadjuvant chemotherapy and subsequently became sarcopenic. Patient demographics, 
clinical indices, and pathological data are summarized in Table 1.
Stratification of patients based on the presence or absence of sarcopenia demonstrated 
that only patient weight and BMI were statistically different between the groups (P=0.036 
and 0.001, respectively). There was no statistical difference in the patients' comorbidities, 
assessed by the ASA-PS and CCI scores (P=0.803 and 0.144, respectively). No statistically 
significant difference was observed in the tumor profile between the patient groups. This 
was assessed by tumor site, stage, and the number of LNs resected. In all, 50% (28 of 56) of 
patients received neoadjuvant chemotherapy and 64.3% (18 of 28) of these patients went on 
to have adjuvant chemotherapy. The seven patients with stage 0 gastric cancer were treated 
surgically and did not receive neoadjuvant chemotherapy. A mean of 28.7 LNs were resected 
in the whole patient cohort. In total, 52 patients (92.9%) of the whole patient cohort had a 
resection of ≥15 LNs. Of the remainder, three patients had stage 1A disease.
The median follow-up time for the whole patient cohort was 39.88 months (interquartile 
range, 17.43–61.2 months). RFS and OS curves for patients with and without sarcopenia 
are shown in Figs. 2 and 3, respectively. No statistically significant difference was observed 
in RFS between patient groups (P=0.084, log-rank test). However, there was a statistically 
significant difference in OS between the 2 groups (P=0.003, log-rank test), with sarcopenic 
patients having reduced survival.
Overall, 20 patients experienced severe post-operative complications (Clavien-Dindo >3A). 
The sarcopenic group had a higher rate of severe complications than the non-sarcopenic group 
(11 patients vs. 9 patients, respectively). Radiologically guided pleural drainage or chest tube 
insertion was required by 8 patients: 3 from the sarcopenic group and 5 from the non-sarcopenic 
group. Surgical intervention under general anesthetic was required by 5 patients for wound 
debridement (n=1), perforation (n=1), tracheostomy insertion (n=1), and small bowel obstruction 
(n=2): 3 from the sarcopenic group and 2 from the non-sarcopenic group. ICU admission was 
required by 7 patients: 5 from the sarcopenic group and 2 from the non-sarcopenic group.
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A summary of univariate and multivariate cox regression analyses for OS is presented in 
Table 2. In the univariate regression analysis, sarcopenia, BMI, and AJCC tumor stages 2A–2B 
and 3A–3C were statistically significant prognosticators of OS. Due to the small study group, 
only the variables that were statistically significant in the univariate analysis were included 
in the multivariate regression analysis. Only sarcopenia and AJCC tumor stages 2A–2B and 
3A–3C were statistically significant predictors of poor OS in the multivariate analysis (hazard 
ratio [HR], 10.915; P=0.001; HR, 50.177, P≤0.001; and HR, 56.377; P≤0.001, respectively).
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Table 1. Clinical indices and pathological data of patients stratified by the presence of pre-operative sarcopenia
Characteristics All Patients (n=56) Sarcopenic (n=20) Non-sarcopenic (n=36) P-value
Age (yr) 68.4±11.9 67.4±12.7 70.3±10.2 0.385*
Sex 0.393†
Male 41 16 25
Female 15 4 11
Height (cm) 168.4±8.8 169±7.5 167±9.5 0.356*
Weight (kg) 73.8±14.8 68.3±11.6 76.9±15.7 0.036*
BMI (kg/m2) 25.9±4.3 23±2.9 27.2±4.4 0.001*
ASA-PS 0.803†
Grade 1 5 2 3
Grade 2 21 8 13
Grade 3 29 10 19
Grade 4 1 0 1
CCI 0.144†
0 5 0 5
1 2 1 1
2 17 7 10
3 11 7 4
4 11 2 9
5 6 2 4
6 3 1 2
7 1 0 1
Neoadjuvant therapy 0.610†
Yes 28 10 18
No 28 10 18
Type of surgery 0.087†
Total gastrectomy 34 16 18
Distal gastrectomy 12 2 10
Proximal gastrectomy 10 2 8
Tumor site 0.416†
Cardia 16 5 11
Fundus 4 2 2
Body 15 8 7
Antrum 14 3 11
Pylorus 7 2 5
Stage 0.282†
0 7 3 4
1A 11 3 8
1B 7 2 5
2A 6 1 5
2B 7 2 5
3A 3 0 3
3B 9 6 3
3C 6 3 3
Number of LNs resected (range) 28.7 (4–75) 28.3 (13–79) 29 (4–58) 0.308‡
Number of positive LNs (range) 2.2 (0–23) 2.05 (0–10) 2.33 (0–23) 0.827‡
Continuous data presented as mean±1 standard deviation unless otherwise stated. Statistically significant values in bold.
BMI = body mass index; ASA-PS = American Society of Anesthesiologists physical status; CCI = Charlson comorbidity index; Stage = overall TNM staging as per 
American Joint Committee on Cancer 7th edition; LN = lymph node.
*Independent t-test, †χ2 test ‡Mann-Whitney U test.
The association between sarcopenia and post-operative morbidity is shown in Table 3. There 
was a statistically significant difference between the 2 groups with respect to serious post-
operative complications (Clavien-Dindo ≥3a) (P=0.025), in-hospital mortality (P=0.041), 
and number of ICU bed days (P=0.007). There was no statistically significant difference in 
the total length of hospital stay between the 2 groups (P=0.373). Univariate and multivariate 
regression analyses were used to identify factors associated with hospital complications 
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No. at risk
Sarcopenic 17 11 6 6 6 6 4
Non-sarcopenic 39 37 34 26 21 16 12


















Fig. 2. Kaplan-Meier analysis for RFS indicated that there was no statistically significant difference in RFS between 
sarcopenic and non-sarcopenic patients (P=0.084, log-rank test). 
RFS = recurrence-free survival.
No. at risk
Sarcopenic 17 11 6 6 6 6 4
Non-sarcopenic 39 39 36 26 24 17 12


















Fig. 3. Kaplan-Meier analysis for OS indicated a statistically significant difference in OS between non-sarcopenic 
and sarcopenic patients (P=0.003, log-rank test). 
OS = overall survival.
(Table 4). In the univariate analysis, being male and having sarcopenia were found to 
be statistically significant factors associated with in-hospital complications (odds ratio 
[OR], 5.087; P=0.048 and OR, 3.667; P=0.028). However, in the multivariate analysis, only 
sarcopenia was found to be a significant prognosticator of serious in-hospital complications 
(OR, 3.508; P=0.042).
DISCUSSION
The role of sarcopenia in the management of patients with cancer is an evolving area of 
research. Numerous studies encompassing different tumor biologies have demonstrated 
that a low skeletal muscle index has an adverse effect on the outcomes of oncology patients. 
Sarcopenia has been associated with increased length of hospital stay, serious in-hospital 
complications, increased inpatient mortality, and lower disease-free survival and OS 
[6,8,19,20].
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Table 2. Univariate and multivariate Cox regression analysis of clinicopathological factors and OS
Characteristics Univariate analysis Multivariate analysis
HR 95% CI P-value HR 95% CI P-value
Age 1.030 0.991–1.070 0.135
Sex 0.605 0.227–1.613 0.315
Height 1.013 0.972–1.056 0.542
Weight 0.981 0.955–1.007 0.144
BMI 0.896 0.809–0.993 0.037 0.894 0.791–1.011 0.074
Sarcopenia 3.885 1.754–8.607 0.001 10.915 3.195–37.288 0.001
ASA-PS group ≥2 0.680 0.310–1.494 0.337
CCI ≥3 1.416 0.625–3.209 0.404
Neoadjuvant therapy 1.255 0.569–2.768 0.573
Type of surgery
Total gastrectomy 1
Distal gastrectomy 1.330 0.467–3.791 0.594
Proximal gastrectomy 1.596 0.609–4.182 0.341
Tumor site
Cardia 1
Fundus 1.225 0.259–5.786 0.798
Body 1.370 0.514–3.687 0.525
Antrum 0.683 0.223–2.093 0.505
Pylorus 0.737 0.156–3.481 0.700
Stage
0–1B 1 1
2A–2B 10.749 2.320–49.804 0.002 50.177 7.682–327.752 <0.001
3A–3C 19.610 4.366–88.079 <0.001 56.377 9.175–346.407 <0.001
Number of LNs resected 1.012 0.979–1.047 0.485
Statistically significant values in bold.
OS = overall survival; HR = hazard ratio; CI = confidence interval; BMI = body mass index; ASA-PS = American Society of Anesthesiologists physical status; CCI = 
Charlson comorbidity index; Stage = overall TNM staging as per American Joint Committee on Cancer 7th edition.
Table 3. Analysis of hospital outcomes by pre-operative sarcopenia
Outcomes All patients (n=56) Sarcopenic (n=20) Non-sarcopenic (n=36) P-value
Serious complications (%) 20 (35.7) 11 (55.0) 9 (25.0) 0.025*
Length of hospital stay 21.46 (7–71) 25.1 (7–57) 19.44 (8–71) 0.373†
Total number of ICU/HDU bed days 6.68 (0–62) 9.45 (0–43) 5.08 (0–62) 0.007†
In-hospital mortality (%) 3 (5.4) 3 (15.0) 0 (0) 0.041‡
Results of length of hospital stay and number of ICU bed days are presented as mean number of days (range). Serious complications (Clavien-Dindo ≥3a) and 
in-hospital mortality are recorded as number (%).
ICU = intensive care unit; HDU = high-dependency unit.
*χ2 test, †Mann-Whitney U test, ‡Fisher's exact test.
The present study investigated the effect of sarcopenia on patients undergoing potentially 
curative surgery for gastric adenocarcinoma with respect to post-operative morbidity, 
RFS, and OS. The study groups were very well-matched and the surgical approach was 
standardized, given that only 1 surgeon was involved. Sarcopenia was adversely associated 
with serious post-operative hospital complications (Clavien-Dindo ≥3a) and decreased 
OS. Interestingly, there was no statistically significant difference observed in the length 
of hospital stay between the patient groups, which was expected due to the association of 
sarcopenia with major in-hospital complications and increased length of stay in the ICU. 
This may be due in part to the small study group. However, the differences observed in the 
incidence of major complications and the number of ICU bed days indicate that sarcopenic 
patients are more resource intensive than non-sarcopenic patients.
Sarcopenic thresholds reported by Prado et al. [17] are frequently referenced and used 
for patient stratification; these are derived from an obese cohort of cancer patients with a 
number of different tumor etiologies. Despite the potential for bias in these cut-off values, 
significant associations with many disease outcomes have been found. This may be due to the 
general population becoming increasingly obese and the study's restriction to obese patients 
may, in fact, be representative of modern society [21]. Hence, it was deemed appropriate to 
use these threshold values for the purposes of the present study. Almost 59% (33 of 56) of 
patients in the present study were overweight or obese and although there was a statistical 
difference in BMI between the 2 patient groups, BMI was not associated with a worse 
outcome in terms of morbidity or survival in the multivariate analysis. A similar finding was 
reported in a study of patients with hepatocellular carcinoma [19]. Cachexia associated with 
cancer is characterized by loss of a muscle mass, which may not be accompanied by a loss of 
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Table 4. Univariate and multivariate regression analyses for risk factors of serious complications (Clavien-Dindo ≥3A)
Characteristics Univariate analysis Multivariate analysis
OR 95% CI P-value OR 95% CI P-value
Age 1.008 0.962–1.057 0.743
Sex (male) 5.087 1.015–25.485 0.048 4.836 0.922–25.361 0.062
Height 1.053 0.985–1.125 0.129
Weight 1.010 0.973–1.048 0.591
BMI 0.979 0.859–1.116 0.752
Sarcopenic 3.667 1.150–11.694 0.028 3.508 1.048–11.739 0.042
ASA-PS ≥3 0.584 0.194–1.760 0.340
CCI ≥3 0.636 0.211–1.918 0.422
Neoadjuvant therapy 0.431 0.139–1.333 0.144
Type of surgery
Total gastrectomy 1
Distal gastrectomy 0.000 0.00–Infinity 0.999
Proximal gastrectomy 2.143 0.509–9.024 0.299
Location of tumor
Cardia 1
Fundus 3.857 0.326–45.570 0.284
Body 1.125 0.273–4.635 0.870
Antrum 0.214 0.036–1.288 0.092
Pylorus 0.214 0.021–2.216 0.196
Stage
0–1B 1
2A–2B 2.204 0.545–8.910 0.267
3A–3C 1.636 0.451–5.936 0.454
Number of LNs resected 0.967 0.918–1.019 0.211
Statistically significant values in bold.
OR = odds ratio; CI = confidence interval; BMI = body mass index; ASA-PS = American Society of Anesthesiologists physical status; CCI = Charlson comorbidity 
index; Stage = overall TNM staging as per American Joint Committee on Cancer 7th edition; LN = lymph node.
fat mass and may be poorly reflected by changes in BMI [22]. With the rising prevalence of 
obesity in the community, sarcopenia may be a more suitable prognostic factor than BMI. 
The use of CT to identify patients who have sarcopenia despite having a normal BMI has not 
been widely exploited. The reporting of skeletal muscle index represents a potential added 
value that radiologists could provide to guide referring physicians.
Some studies have failed to demonstrate these relationships; a recent study that 
investigated the effect of sarcopenia on patients with gastric cancer undergoing surgery 
did not show an association between sarcopenia and short-term post-operative morbidity 
and mortality [23]. There are fundamental differences in the profile of patients' in that study: 
57.7% of patients in that study were sarcopenic compared with only 35.7% in the present 
study, and 30.6% of patients in that study underwent palliative surgery, with 37.1% having 
stage 4 disease, whereas the present study group was restricted to those undergoing 
curative surgery. These differences may explain the different study results. Another recent 
paper reported that sarcopenia is associated with decreased OS in esophago-gastric cancer 
patients [24]. The incidence of sarcopenia in that study was 49.4% and a larger variety 
of cancers were studied (esophageal, esophago-gastric junction, and gastric cancers) in 
comparison to the present, more focused study.
The incorporation of skeletal muscle index calculation into pre-operative risk stratification 
and prognostic models may require tumor-specific cut-off values for a low skeletal muscle 
index. Tumor pathophysiology and prognosis can vary widely, as can the physiologic 
challenge of surgery. The concept of tumor-specific values has been investigated in several 
studies. An adverse association has been demonstrated between sarcopenia and RFS and 
OS in patients with colorectal cancer [25]. Similarly, an association between sarcopenia and 
OS in patients with pancreatic cancer has also been shown [26]. Both of these studies used 
the lowest sex-specific quartile to define a low skeletal muscle index.
The identification of patients who are sarcopenic at the time of diagnosis may aid 
the selection of patients for early nutritional and physical intervention. This might 
be particularly suitable for patients with gastric cancer who require neoadjuvant 
chemotherapy. In a study which analyzed the change in body composition in patients after 
neoadjuvant chemotherapy for esophago-gastric cancer, there was a statistically significant 
increase in the number of patients with sarcopenia post-chemotherapy [27]. This was 
reflected in the present study with previously non-sarcopenic patients becoming sarcopenic 
post-chemotherapy.
The present study included consecutive patients who underwent curative surgery for 
gastric cancer at a single tertiary referral center. The study was retrospective and although 
comparable with similar papers studying other cancers, the patient group was relatively 
small. A multicenter prospective study with a larger patient population may be necessary to 
better elucidate the association between sarcopenia and post-operative outcomes in specific 
subgroups of patients undergoing curative resection for gastric cancer.
The relationship between the systemic inflammatory response and sarcopenia and its 
influence on this study's findings were not included due to lack of relevant data (C-reactive 
protein, etc.). Results from the recent C-SCANS study indicated that pre-diagnosis systemic 
inflammation and at-diagnosis sarcopenia were associated with an increased mortality 
risk in patients with non-metastatic colorectal cancer [28]. Further study of the influence of 
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the systemic inflammatory response on skeletal muscle in gastric cancer may help guide 
interventions to prevent sarcopenia and potentially improve survival outcomes.
In conclusion, the present study demonstrated that, in patients undergoing curative 
resection for gastric cancer, there was a statistically significant association between 
sarcopenia and both decreased OS and serious post-operative complications. The 
measurement and reporting of skeletal muscle index from pre-operative CT should be 
considered for patient preparation purposes.
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